Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Por Sandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, Arlene Hurley, Angela Lombardo, Soe Than, Phumla Adesanya, Catherine Bunce, Mark Boaz, Rosanne Boyle, Eddy Sayeed, Lorna Clark, Daniel Dugin, Mar Boente-Carrera, Claudia Schmidt, Qing Fang, LeiBa, Yaoxing Huang, Gerasimos J Zaharatos, David F Gardiner, Marina Caskey, Laura Seamons, Martin Ho, Len Dally, Carol Smith, Josephine Cox, Dilbinder Gill, Jill Gilmour, Michael C Keefer, Patricia Fast, David D Ho
Publicado em 2010-01-01